Uttar Pradesh Uncovers ₹700 Crore Cough Syrup Racket, Calls for Stricter Drug Rules
UP unearths ₹700 crore cough syrup racket, prompting calls for tighter drug regulation.
Photo by Abhishek Tewari
Uttar Pradesh's drug regulator has uncovered a massive ₹700 crore cough syrup racket, involving the diversion of pharmaceutical-grade codeine-based cough syrup to the illicit drug market. This sophisticated operation highlights significant loopholes in the current drug regulatory framework, enabling manufacturers and distributors to exploit the system.
The UP Food Safety and Drug Administration (FSDA) has proposed stricter rules, including mandatory CCTV cameras at manufacturing units, real-time tracking of raw materials, and enhanced coordination between state and central agencies. This incident underscores the urgent need for robust drug control mechanisms to prevent public health crises and combat the growing menace of drug abuse.
Key Facts
₹700 crore cough syrup racket uncovered in Uttar Pradesh
Involves diversion of codeine-based cough syrup
UP FSDA proposed stricter rules: mandatory CCTV, real-time tracking, enhanced inter-agency coordination
UPSC Exam Angles
Drug regulatory framework in India (Acts, bodies, responsibilities)
Federalism in drug control (Centre-State relations and coordination)
Public health implications of drug abuse and illicit trade
Governance challenges: enforcement, transparency, accountability in regulatory bodies
Role of technology in strengthening regulatory oversight and supply chain management
Social justice aspect: impact of drug abuse on vulnerable populations
Visual Insights
Uttar Pradesh: Epicentre of ₹700 Cr Cough Syrup Racket
This map highlights Uttar Pradesh, the state where a massive ₹700 crore cough syrup racket was uncovered. Its strategic location, large population, and borders make it a critical region for drug control and enforcement.
Loading interactive map...
Key Statistics: Uttar Pradesh Cough Syrup Racket & Regulatory Response
This dashboard summarizes the scale of the illicit cough syrup racket and the key regulatory reforms proposed by the UP FSDA, highlighting the urgent need for enhanced drug control mechanisms.
- Racket Value Uncovered
- ₹700 Crore
- Primary Substance Involved
- Codeine-based Cough Syrup
- Proposed Regulatory Measure 1
- Mandatory CCTV Cameras
- Proposed Regulatory Measure 2
- Real-time Tracking of Raw Materials
- Identified Regulatory Gap
- Loopholes in Current Framework
Indicates the massive scale of diversion of pharmaceutical-grade codeine-based cough syrup to the illicit drug market.
Highlights the misuse of controlled pharmaceutical substances, often diverted from legitimate channels.
A key proposal by UP FSDA to enhance transparency and surveillance at manufacturing units, preventing diversion at source.
Aims to create an end-to-end digital trail for controlled substances, making diversion difficult and traceable.
The racket exploited weaknesses in existing drug laws and enforcement, necessitating comprehensive reforms.
More Information
Background
India is a significant global pharmaceutical manufacturer, often referred to as the 'pharmacy of the world'. This position, while beneficial, also brings challenges related to quality control, illicit trade, and diversion of pharmaceutical products for abuse.
The regulatory framework for drugs in India is primarily governed by the Drugs and Cosmetics Act, 1940, and the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Codeine-based cough syrups, due to their opioid content, are classified as controlled substances, making their regulation a complex interplay between these two acts and requiring stringent oversight to prevent misuse.
Latest Developments
Practice Questions (MCQs)
1. Consider the following statements regarding the regulation of drugs in India: 1. The Central Drugs Standard Control Organisation (CDSCO) is responsible for the approval of new drugs and clinical trials, while State Drug Control Organizations regulate manufacturing and sales licenses. 2. The Drugs and Cosmetics Act, 1940, and Rules thereunder, primarily govern the manufacture, sale, and distribution of all pharmaceutical products, including those containing narcotic substances. 3. Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, completely supersedes the Drugs and Cosmetics Act for any substance classified as a narcotic or psychotropic, even if used for medicinal purposes.
- A.1 only
- B.1 and 2 only
- C.2 and 3 only
- D.1, 2 and 3
Show Answer
Answer: B
Statement 1 is correct. CDSCO handles central approvals, while state bodies manage local licensing and enforcement. Statement 2 is correct. The Drugs and Cosmetics Act provides the overarching framework for quality, manufacturing, and sale of all drugs. Statement 3 is incorrect. While the NDPS Act specifically deals with the control of narcotic drugs and psychotropic substances, their manufacturing, quality, and sale for medicinal purposes still fall under the purview of the Drugs and Cosmetics Act. The two acts operate concurrently, with the NDPS Act imposing additional, stricter controls on specific substances.
2. In the context of the recent cough syrup racket and drug abuse, which of the following statements about codeine and its regulation in India is correct?
- A.Codeine is classified as a Schedule H drug under the Drugs and Cosmetics Rules, requiring a prescription for sale, and is also listed under the NDPS Act.
- B.All codeine-based formulations are strictly prohibited for manufacture and sale in India under the Narcotic Drugs and Psychotropic Substances (NDPS) Act.
- C.State governments have the sole authority to regulate the possession and sale of codeine-based cough syrups within their borders, independent of central laws.
- D.The NDPS Act, 1985, primarily focuses on the illicit trafficking of narcotic drugs and does not cover their legitimate use for medicinal or scientific purposes.
Show Answer
Answer: A
Statement A is correct. Codeine is indeed a Schedule H drug, requiring a prescription, and is also a controlled substance under the NDPS Act due to its potential for abuse. Statement B is incorrect; codeine-based formulations are allowed for medicinal use under strict regulations. Statement C is incorrect; drug regulation, especially for controlled substances, involves both central and state authorities, with central laws like the NDPS Act and Drugs and Cosmetics Act providing the overarching framework. Statement D is incorrect; the NDPS Act does provide provisions for the legitimate use of narcotic drugs for medicinal and scientific purposes, albeit under stringent controls and licenses.
3. The Uttar Pradesh FSDA has proposed measures like mandatory CCTV cameras at manufacturing units and real-time tracking of raw materials. These measures are primarily aimed at addressing which of the following challenges in India's drug regulatory system? 1. Lack of transparency and traceability in the pharmaceutical supply chain. 2. Difficulty in identifying diversion points for illicit trade and abuse. 3. Absence of a robust, centralized digital database for drug manufacturers and distributors. 4. Inadequate inter-state coordination among drug control agencies.
- A.1 and 2 only
- B.2 and 3 only
- C.1, 2 and 3 only
- D.1, 2, 3 and 4
Show Answer
Answer: C
Statements 1, 2, and 3 are directly addressed by the proposed measures. Mandatory CCTV and real-time tracking enhance transparency and traceability (1), making it easier to pinpoint where diversion occurs (2). Such systems inherently contribute to building a more robust digital database (3) by collecting real-time data. While 'inadequate inter-state coordination' (4) is a significant challenge in drug control, the specific measures of CCTV and real-time tracking, by themselves, do not *primarily* address inter-state coordination, although they can provide data that facilitates better coordination. The primary focus of these technological interventions is on internal supply chain integrity and monitoring.